"Trojan Horse" Tested in EGFR-Amplified Glioblastoma
Published: Thursday, Jul 06, 2017
Martin J. Van Den Bent, MD
Investigators are seeking to determine whether the addition of ABT-414, an antibody–drug conjugate, to concomitant radiotherapy and temozolomide will improve the survival of patients with newly diagnosed glioblastoma multiforme (GBM) with epidermal growth factor receptor (EGFR) amplification.
... to read the full story